Compare VTAK & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTAK | GOVX |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.7M |
| IPO Year | 2018 | N/A |
| Metric | VTAK | GOVX |
|---|---|---|
| Price | $1.38 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $200.00 |
| AVG Volume (30 Days) | 64.8K | ★ 126.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $442,000.00 | N/A |
| Revenue This Year | $822.86 | N/A |
| Revenue Next Year | $168.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3057.14 | N/A |
| 52 Week Low | $0.15 | $0.12 |
| 52 Week High | $4.31 | $4.40 |
| Indicator | VTAK | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 49.20 |
| Support Level | $1.14 | $0.55 |
| Resistance Level | $2.05 | $4.40 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.67 | 82.95 |
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.